Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC).

Burn J, Mathers J, Bishop DT.

Recent Results Cancer Res. 2013;191:157-83. doi: 10.1007/978-3-642-30331-9_9. Review.

PMID:
22893205
2.

Chemoprevention of colorectal cancer: systematic review and economic evaluation.

Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, Maguire C, Hind D, Tappenden P.

Health Technol Assess. 2010 Jun;14(32):1-206. doi: 10.3310/hta14320. Review.

3.

A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis.

Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, Dunlop MG, Eccles D, Ellis A, Evans DG, Fodde R, Maher ER, Möslein G, Vasen HF, Coaker J, Phillips RK, Bülow S, Mathers JC; International CAPP consortium.

Cancer Prev Res (Phila). 2011 May;4(5):655-65. doi: 10.1158/1940-6207.CAPR-11-0106.

4.

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.

Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JW, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJ, Vasen HF, Barker G, Crawford G, Elliott F, Movahedi M, Pylvanainen K, Wijnen JT, Fodde R, Lynch HT, Mathers JC, Bishop DT; CAPP2 Investigators.

Lancet. 2011 Dec 17;378(9809):2081-7. doi: 10.1016/S0140-6736(11)61049-0. Epub 2011 Oct 27.

5.

Chemoprevention in Lynch syndrome.

Burn J, Mathers JC, Bishop DT.

Fam Cancer. 2013 Dec;12(4):707-18. doi: 10.1007/s10689-013-9650-y.

PMID:
23880960
6.

Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.

Mathers JC, Movahedi M, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans G, Maher ER, Bertario L, Bisgaard ML, Dunlop M, Ho JW, Hodgson S, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJ, Vasen H, Gerdes AM, Barker G, Crawford G, Elliott F, Pylvanainen K, Wijnen J, Fodde R, Lynch H, Bishop DT, Burn J; CAPP2 Investigators.

Lancet Oncol. 2012 Dec;13(12):1242-9. doi: 10.1016/S1470-2045(12)70475-8. Epub 2012 Nov 7.

7.

Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.

Burn J, Bishop DT, Mecklin JP, Macrae F, Möslein G, Olschwang S, Bisgaard ML, Ramesar R, Eccles D, Maher ER, Bertario L, Jarvinen HJ, Lindblom A, Evans DG, Lubinski J, Morrison PJ, Ho JW, Vasen HF, Side L, Thomas HJ, Scott RJ, Dunlop M, Barker G, Elliott F, Jass JR, Fodde R, Lynch HT, Mathers JC; CAPP2 Investigators.

N Engl J Med. 2008 Dec 11;359(24):2567-78. doi: 10.1056/NEJMoa0801297. Erratum in: N Engl J Med. 2009 Apr 2;360(14):1470.

8.

Can resistant starch and/or aspirin prevent the development of colonic neoplasia? The Concerted Action Polyp Prevention (CAPP) 1 Study.

Mathers JC, Mickleburgh I, Chapman PC, Bishop DT, Burn J; Concerted Action Polyp Prevention (CAPP) 1 Study.

Proc Nutr Soc. 2003 Feb;62(1):51-7. Review.

PMID:
12740057
9.

Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study.

Movahedi M, Bishop DT, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JW, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar RS, Side L, Scott RJ, Thomas HJ, Vasen HF, Burn J, Mathers JC.

J Clin Oncol. 2015 Nov 1;33(31):3591-7. doi: 10.1200/JCO.2014.58.9952. Epub 2015 Aug 17.

PMID:
26282643
10.

Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial.

Ishikawa H, Wakabayashi K, Suzuki S, Mutoh M, Hirata K, Nakamura T, Takeyama I, Kawano A, Gondo N, Abe T, Tokudome S, Goto C, Matsuura N, Sakai T.

Cancer Med. 2013 Feb;2(1):50-6. doi: 10.1002/cam4.46. Epub 2013 Feb 3.

11.

Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas.

Asano TK, McLeod RS.

Cochrane Database Syst Rev. 2004;(2):CD004079. Review.

PMID:
15106236
12.

Cohorts with familial disposition for colon cancers in chemoprevention trials.

Burt RW.

J Cell Biochem Suppl. 1996;25:131-5. Review.

PMID:
9027609
15.

[Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].

Sheng JQ, Li SR, Yang XY, Zhang YH, Su H, Yu DL, Yan W, Geng HG.

Zhonghua Yi Xue Za Zhi. 2006 Feb 28;86(8):526-9. Chinese.

PMID:
16681880
16.

Chemoprevention of hereditary colon cancers: time for new strategies.

Ricciardiello L, Ahnen DJ, Lynch PM.

Nat Rev Gastroenterol Hepatol. 2016 Jun;13(6):352-61. doi: 10.1038/nrgastro.2016.56. Epub 2016 Apr 20. Review.

PMID:
27095653
17.

Lynch syndrome: history, causes, diagnosis, treatment and prevention (CAPP2 trial).

Burn J, Mathers J, Bishop DT.

Dig Dis. 2012;30 Suppl 2:39-47. doi: 10.1159/000341892. Epub 2012 Nov 23.

PMID:
23207931
18.
19.

Genetics of hereditary colorectal cancer.

Jo WS, Chung DC.

Semin Oncol. 2005 Feb;32(1):11-23. Review.

PMID:
15726502
20.

Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial.

Samadder NJ, Neklason DW, Boucher KM, Byrne KR, Kanth P, Samowitz W, Jones D, Tavtigian SV, Done MW, Berry T, Jasperson K, Pappas L, Smith L, Sample D, Davis R, Topham MK, Lynch P, Strait E, McKinnon W, Burt RW, Kuwada SK.

JAMA. 2016 Mar 22-29;315(12):1266-75. doi: 10.1001/jama.2016.2522.

Supplemental Content

Support Center